论文部分内容阅读
摘要目的明确影响经皮穿刺射频消融(RFA)治疗结直肠癌肝转移(CLM)预后的因素,并描述和评价适用于消融术后病人分级及判断预后的改良版临床风险评分(CRS)。材料与方法本研究由HIPAA兼容的机构审查通过,回顾性分析从2002年12月—2012年12月收集的162例病人的233个CLM。射频消融术后4~8周行CT增强检查评估治疗效
Abstract Objective To clarify the factors influencing the prognosis of colorectal cancer liver metastasis (CLM) by percutaneous puncture radiofrequency ablation (RFA) and to describe and evaluate the modified clinical risk score (CRS) which is applicable to the patient classification and the prognosis after ablation. Materials and Methods The study was reviewed by HIPAA-compliant institutions and retrospectively analyzed 233 CLMs of 162 patients collected from December 2002-December 2012. 4 to 8 weeks after radiofrequency ablation CT enhanced examination evaluation of the curative effect